Survival after starting renal replacement treatment in patients with autosomal dominant polycystic kidney disease: A single-centre 40-year study

Nephron - Clinical Practice

Volumn 120, Issue 1, 2012, Pages

  Haynes, Richard ^a   Kheradmand, Farhad ^a   Winearls, Christopher G ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Adult polycystic kidney disease; Dialysis; Survival; Transplant

Indexed keywords

ADULT; AUTOSOMAL DOMINANT DISORDER; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY POLYCYSTIC DISEASE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POPULATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; REVIEW;

ADULT; COHORT STUDIES; COMORBIDITY; CYCLOSPORINE; ENGLAND; FEMALE; HEMATINICS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIFE EXPECTANCY; MALE; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROPORTIONAL HAZARDS MODELS; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84859431420     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000334429     Document Type: Review

References (17)

1. Farrington K, Udayaraj U, Gilg J, Feehally J: UK Renal Registry 11th Annual Report (December 2008). Chapter 3: ESRD incident rates in 2007 in the UK: national and centrespecific analyses. Nephron Clin Pract 2009; 111(suppl 1):c13-41.
2. Hateboer N, van Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, et al: Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999; 353: 103-107. (Pubitemid 29088079)
3. Torres VE, Harris PC: Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009; 76: 149-168.
4. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LYC, et al: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-1730.
5. Kasiske BL, Chakkera HA, Louis TA, Ma JZ: A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910-1917.
6. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al: Metaanalysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010; 153: 23-33.
7. Udayaraj U, Tomson CR, Gilg J, Ansell D, Fogarty D: UK Renal Registry 11th Annual Report (December 2008). Chapter 6: Comorbidities and current smoking status amongst patients starting renal replacement therapy in England, Wales and Northern Ireland: national and centre-specific analyses. Nephron Clin Pract 2009; 111(suppl 1):c97-111.
8. Ansell D, Roderick P, Hodsman A, Ford D, Steenkamp R, Tomson C: UK Renal Registry 11th Annual Report (December 2008). Chapter 7: Survival and causes of death of UK adult patients on renal replacement therapy in 2007: national and centre-specific analyses. Nephron Clin Pract 2009; 111(suppl 1):c113-139.
9. US Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006.
10. Grantham JJ: Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 2008; 359: 1477-1485.
11. US Renal Data System. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009.
12. Schrier RW, McFann KK, Johnson AM: Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int 2003; 63: 678-685. (Pubitemid 36126815)
13. Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW: Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2000; 35: 427-432.
14. Jafar TH, Stark PC, Schmid CH, Strandgaard S, Kamper AL, Maschio G, et al: The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int 2005; 67: 265-271. (Pubitemid 40019248)
15. Patch C, Charlton J, Roderick PJ, Gulliford MC: Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. Am J Kidney Dis 2011; 57: 856-862.
16. Orskov B, Romming Sorensen V, Feldt-Rasmussen B, Strandgaard S: Improved Prognosis in patients with autosomal dominant polycystic kidney disease in Denmark. Clin J Am Soc Nephrol 2010; 5: 2034-2039.
17. Jaar BG: The Achilles heel of mortality risk by dialysis modality is selection bias. J Am Soc Nephrol 2011; 22: 1398-1400.